MPManya Prasad

Manya Prasad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manya Prasad has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Letter on: Pre‐Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. Authors' Reply

    by Rakhi Maiwall, Meenu Bajpai, Samba Siva Rao Pasupuleti, Neha Chauhan, Mohit Prajapati, Manya Prasad, Prashant Agarwal, Rajendra Prasad Mathur, Sherin Thomas, Shiv Kumar Sarin

  • Open Access

    Clinicians’ decisions about antibiotic treatment in advanced dementia: an international survey

    by João Pedro Lima, Lawrence Mbuagbaw, Manya Prasad, Amit Kumar, Guy Sadeu Wafeu, Romain Bonnet, Thomas Agoritsas, Sheyu Li, Zhanming Liu, Pablo Alonso-Coello, et al.

    Objectives: In patients living with advanced dementia, the intensity of care during life-threatening infections remains controversial and marked by wide variation in practice. This international survey investigated physicians’ and physicians-in-training’s management choices for individuals with advanced dementia and the factors associated with those choices. Design: Vignette-based survey. Setting: Twelve countries across five continents. Methods: We administered our vignette-based survey to medical students, residents and physicians. The survey elicited participants’ views on whether antibiotics should be administered to an elderly patient with advanced dementia and very poor quality of life, presenting with bacterial pneumonia. We explored factors associated with treatment choices using univariable analysis and multiple logistic regression models. Results: Of the 785 participants (age, mean (SD): 31.1 (11.5) years), one-third (31.2%) resided in the Region of the Americas, 21.9% in Europe, 16.2% in the Eastern Mediterranean region and 17.1% in China. In the univariable analysis, choice to treat was associated with younger age, country/WHO region (African region highest overall, European region lowest overall), stage of medical training (medical student most inclined to treat) and absence of medical assistance in dying (MAiD) legislation. Multivariable analyses provided evidence that country was the variable most strongly associated with the choice to treat with antibiotics (Cameroon, China, Saudi Arabia highest; Norway, Switzerland, Spain lowest), with the presence of MAiD legislation also strongly associated (OR 0.35, 95% CI 0.23 to 0.51). Age (OR 0.82, 95% CI 0.66 to 1.00) and religiosity level (OR 0.93, 95% CI 0.87 to 0.99) showed weaker associations with treatment decisions. Conclusion: Inclination to treat individuals with advanced dementia who develop pneumonia varies greatly between and within jurisdictions. Social factors (in particular country but also presence of MAiD legislation) proved the most prominent associations, with individual characteristics much less influential. These findings underscore the importance of contextual and cultural factors in value-sensitive clinical decisions. Registration: We registered the protocol at Open Science Framework (osf.io/6kfbt).

  • Baveno VII algorithm can be used to exclude varices needing treatment in MASLD related compensated advanced chronic liver disease patients

    by Chitranshu Vashishtha, Ankit Bhardwaj, Shalini Thapar Laroia, Manya Prasad, Ankur Jindal, Manoj Kumar Sharma, Shiv Kumar Sarin


  • Open Access

    Stem cell therapies for liver cirrhosis: a GRADE evaluation through a systematic review

    by Manya Prasad, Priyanka Shenoy, Tushar Prabhakar, Sunanda Gupta, Surbhi Gupta, Sumridhi Gautam, Vinamrata Kapoor Ghai, Saraa Angel L, Keerthi Keerthi, Saumya Vats, et al.

  • Open Access

    Duration of anti-seizure medicines started for acute symptomatic seizures due to acute meningitis: a systematic review and meta-analysis

    by Manya Prasad, Amit Kumar, Rachel Couban, Nicoline Schiess, Kavita Kothari, Elaine Brohan, Nicolo Binello, Francesco Venuti, Tarun Dua

    Background: Acute symptomatic seizures (ASS), a frequent complication of meningitis, are potentially life-threatening and are a predictor of epilepsy if not managed appropriately. The optimal duration of anti-seizure medicines (ASM) in these patients remains unclear. This systematic review evaluates the evidence for earlier versus later cessation of ASM in patients with meningitis who experience ASS. Methods: A comprehensive literature search was conducted across Medline via OVID, Embase via OVID, Cochrane CENTRAL, Web of Science, and ClinicalTrials.gov. Eligible studies included randomized controlled trials and cohort studies that compared ASM cessation within 3 months of initiation of treatment to cessation beyond 3 months. Pooled estimates for outcomes including epilepsy development, seizure recurrence, and adverse events were calculated using random-effects meta-analysis. The certainty of evidence was assessed using the GRADE methodology. Results: Out of 4283 records screened for eligibility, none were found to provide direct evidence in people with meningitis. Two studies on people with encephalitis were included in the meta-analysis as indirect evidence. A randomized controlled trial (RCT) compared 4 weeks versus 12 weeks of ASM in children with acute encephalitis syndrome, while a cohort study investigated ASM duration in adults, including a subset with bacterial meningitis. Both studies found no significant difference in seizure recurrence between earlier and later cessation groups. The pooled risk ratio for seizure recurrence was 1.14 (95% CI, 0.26–5.01). The certainty of the evidence was very low due to indirectness and imprecision. Indirect evidence from other causes of ASS was inconclusive with regard to the duration of ASM. Conclusions: The available evidence is inconclusive with regard to the difference between early and late ASM cessation in reducing seizure recurrence. Due to very low certainty of evidence, individualized clinical judgment remains crucial. Further research, specifically targeting bacterial meningitis, is needed to clarify optimal ASM duration in this population.


  • Open Access

    India’s HPV vaccine rollout: from a welcome launch to an elimination strategy

    by Manya Prasad, Umesh Kapil, Pradeep Aggarwal

    India’s recent nationwide rollout of human papillomavirus (HPV) vaccination marks an important moment in cancer prevention. The national campaign, launched in February 2026, offers a single dose of quadrivalent HPV vaccine to eligible 14-year-old girls free of cost through government health facilities, with plans to continue vaccine availability through routine immunisation sessions after the initial campaign phase (1,2). Prophylactic HPV vaccines are most effective when administered before exposure to infection, making early adolescent vaccination central to prevention. In its 2022 position paper, the World Health Organization (WHO) recommended a one- or two-dose schedule for girls aged 9–14 years, with HPV vaccination positioned as a foundational pillar of the global strategy to eliminate cervical cancer as a public health problem (3). Importantly, India has contributed directly to the evidence supporting a single-dose approach. A multicentre prospective cohort study from India reported that a single dose of quadrivalent HPV vaccine provided high protection against persistent HPV 16/18 infection at 10 years, with efficacy comparable to two- and three-dose schedules (4).


  • Open Access

    Detection of sequelae from acute meningitis during clinical review by a healthcare provider: a systematic review and meta-analysis

    by Luisa F. Alviz, Carla Y. Kim, Lauren E. Monette, Caroline E. Harrer, Ana Claudia Benevides-Tadinac, Jackson A. Roberts, Francisco J. Varela, Soonmyung A. Hwang, Blen M. Gebresilassie, Pilar Balcarce, et al.

    Neurological sequelae from acute meningitis are estimated to affect more than 30% of survivors worldwide, though often underreported or undetected due to i


  • Open Access

    Impact of Iron supplementation in Treatment of Anemia

    by Manya Prasad, Umesh Kapil

    Impact of Iron supplementation in Treatment of Anemia

  • Open Access

    Contextual factors for prevention and management of obesity in India

    by Manya Prasad, Saraa L Angel, Vinamrata Kapoor Ghai, Keerthi, Saumya Vats, Umesh Kapil

    When the Prime Minister recently described obesity as a ‘silent crisis’ for India, it elevated the issue from a clinical concern to a matter of national policy priority (1). Obesity is now widely recognized as a formidable public health challenge in India, with prevalence rising rapidly in both urban and rural settings. As of 2025, India is preparing its first national obesity guideline, aiming to shift the focus beyond global standards to a home-grown framework that accounts for prevention, early diagnosis, and culturally appropriate interventions (2). A recurring theme in this discourse is whether lower BMI thresholds—such as ≥23 kg/m² for overweight and ≥25 kg/m² for obesity—should be formally adopted in place of the WHO’s international cut-offs (≥25 and ≥30, respectively). The cut-off debate: While several expert consensus statements and smaller studies support the use of lower thresholds for Asian Indians, the evidence remains fragmented. Some cross-sectional studies suggest that cardiometabolic risk factors, including diabetes and hypertension, cluster at BMI levels well below 30 kg/m² (3). Yet, large-scale cohort data directly linking these lower cut-offs with incident cardiovascular events and mortality in Indian populations are still limited. As such, the question of optimal thresholds remains open and could be a focus of systematic research rather than a settled matter.